Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Flammini

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Pharmaceutics|March 29, 2023
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In VitroDavide D'Angelo, Eride Quarta, Stefania Glieca, et al.
Biochemical Pharmacology|February 15, 2026
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptorsAndrea Blesio, Carmine Giorgio, Francesca Romana Ferrari, et al.
Journal of Medicinal Chemistry|October 3, 2015
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane RingAlessandro Bonifazi, Fabio Del Bello, Valerio Mammoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.
Cells|July 2, 2021
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal CellsValentina Coccè, Silvia La Monica, Mara Bonelli, et al.
Scientific Reports|March 19, 2024
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell modelsSilvia La Monica, Federica Vacondio, Kamal Eltayeb, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Pharmaceutics|March 29, 2023
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In VitroDavide D'Angelo, Eride Quarta, Stefania Glieca, et al.
Biochemical Pharmacology|February 15, 2026
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptorsAndrea Blesio, Carmine Giorgio, Francesca Romana Ferrari, et al.
Journal of Medicinal Chemistry|October 3, 2015
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane RingAlessandro Bonifazi, Fabio Del Bello, Valerio Mammoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.
Cells|July 2, 2021
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal CellsValentina Coccè, Silvia La Monica, Mara Bonelli, et al.
Scientific Reports|March 19, 2024
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell modelsSilvia La Monica, Federica Vacondio, Kamal Eltayeb, et al.
Pageof 5